DES Outcomes: The Winner of the Sprint Does Not Necessarily Win the Marathon

Five-year results of SORT OUT III illustrate the need for long-term follow-up to elucidate the full safety and efficacy profiles of drug-eluting stents.

Limitations of early drug-eluting stents (DESs) such as late stent thrombosis and evidence of delayed neointimal healing have prompted the development of DESs with new platform materials, thinner stent struts, more-biocompatible or more-biodegradable surface polymer coatings, and less-potent antiproliferative drugs. However, in the manufacturer-funded SORT OUT III trial, risks for both definite stent thrombosis and target-vessel revascularization (TVR) were significantly higher with the second-generation zotarolimus-eluting stent (ZES) than with the first-generation sirolimus-eluting stent (SES) during the first year after implantation (NEJM JW Cardiol Mar 15 2010).

Now, researchers present 5-year clinical outcomes of the SORT OUT III study.…

Reviewing Author

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

Beat J. Meyer, MD

Disclosures

Leadership positions in professional societiesBern Heart Foundation (President); International Academy of Medicine, Bern, Switzerland (Director)

DES Outcomes: The Winner of the Sprint Does Not Necessarily Win the Marathon

Topics

Reviewing Author